Clearside Biomedical (CLSD)
(Real Time Quote from BATS)
$1.14 USD
-0.01 (-0.44%)
Updated Sep 25, 2024 12:40 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 1 - 20 ( 277 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 3 Data of XIPERE Reported in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Reiterate Buy; Modulating PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23: Focus Remains on Advancing the Ph2b ODYSSEY Trial Toward a Q3 Readout
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b Wet AMD Trial Completes Randomization; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q3:23 Financials; Ph2b ODYSSEY Trial Underway for CLS-AX/wAMD, Readout in Q3:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
New License Deal; Positive Clinical Update From Partner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b Wet AMD Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Phase 2b Trial Enrollment Underway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q2: On-Track for a Topline Ph2b ODYSSEY Readout for CLSAX/ wAMD in Q3:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A